Recently, a research group led by Prof. HUANG Chaoqun from the Hefei lnstitutes of Physical Science of the Chinese Academy of Sciences, developed an innovative dual drift tube ion mobility spectrometry (DDT-IMS) technology.
FDA expands Novartis’ Kisqali label to include early breast cancer patients
The FDA first approved Kisqali and aromatase inhibitor combination therapy in postmenopausal HR+/HER2- advanced or metastatic breast cancer patients, in 2017. Image credit: JHVEPhoto /